J
Jessica Buijs-Gladdines
Researcher at Boston Children's Hospital
Publications - 13
Citations - 1416
Jessica Buijs-Gladdines is an academic researcher from Boston Children's Hospital. The author has contributed to research in topics: Protein kinase B & T cell. The author has an hindex of 6, co-authored 11 publications receiving 1265 citations.
Papers
More filters
Journal ArticleDOI
A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study
Monique L. den Boer,Marjon van Slegtenhorst,Renee X. de Menezes,Renee X. de Menezes,Meyling Cheok,Jessica Buijs-Gladdines,Susan T C J M Peters,Laura J. C. M. van Zutven,H. Berna Beverloo,Peter J. van der Spek,Gaby Escherich,Martin A. Horstmann,Gritta Janka-Schaub,Willem A. Kamps,William E. Evans,Rob Pieters +15 more
TL;DR: A genome-wide study to improve prognostic classification of ALL in children revealed a new ALL subtype, the underlying genetic abnormalities of which were characterised by comparative genomic hybridisation-arrays and molecular cytogenetics.
Journal ArticleDOI
Integrated Transcript and Genome Analyses Reveal NKX2-1 and MEF2C as Potential Oncogenes in T Cell Acute Lymphoblastic Leukemia
Irene Homminga,Rob Pieters,Anton W. Langerak,Johan J. de Rooi,Andrew P. Stubbs,Monique Verstegen,Maartje Vuerhard,Jessica Buijs-Gladdines,Clarissa Kooi,Petra Klous,Petra Klous,Pieter Van Vlierberghe,Adolfo A. Ferrando,Jean Michel Cayuela,Brenda Verhaaf,H. Berna Beverloo,Martin A. Horstmann,Valerie de Haas,Anna-Sophia Wiekmeijer,Karin Pike-Overzet,Frank J. T. Staal,Wouter de Laat,Wouter de Laat,Jean Soulier,François Sigaux,Jules P.P. Meijerink +25 more
TL;DR: NKX2-1, NKX22-2, and MEF2C are proposed as T-ALL oncogenes that are activated by various rearrangements.
Journal ArticleDOI
The significance of PTEN and AKT aberrations in pediatric T-cell acute lymphoblastic leukemia
Linda Zuurbier,Emanuel F. Petricoin,Emanuel F. Petricoin,Maartje Vuerhard,Valerie S. Calvert,Clarissa Kooi,Jessica Buijs-Gladdines,Willem K. Smits,Edwin Sonneveld,Anjo J.P. Veerman,Willem A. Kamps,Martin A. Horstmann,Rob Pieters,Jules P.P. Meijerink +13 more
TL;DR: In this article, the impact of PTEN, PI3K and AKT aberrations was studied in a genetically well-characterized pediatric T-cell leukemia patient cohort (n=146) treated on DCOG or COALL protocols.
Journal ArticleDOI
MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia.
Kirsten Canté-Barrett,J.A.P. Spijkers-Hagelstein,Jessica Buijs-Gladdines,Joost C.M. Uitdehaag,Willem K. Smits,J. van der Zwet,R.C. Buijsman,G.J.R. Zaman,Rob Pieters,Jules P.P. Meijerink +9 more
TL;DR: It is shown that inhibiting both the MEK and PI3K-AKT pathways synergistically prevents the proliferation of BaF3 cells expressing mutant IL7Ra, JAK and RAS.
Journal ArticleDOI
Immature MEF2C-dysregulated T-cell leukemia patients have an early T-cell precursor acute lymphoblastic leukemia gene signature and typically have non-rearranged T-cell receptors
Linda Zuurbier,Alejandro Gutierrez,Charles G. Mullighan,Kirsten Canté-Barrett,A. Olivier Gevaert,Johan J. de Rooi,Yunlei Li,Willem K. Smits,Jessica Buijs-Gladdines,Edwin Sonneveld,A. Thomas Look,Martin A. Horstmann,Rob Pieters,Jules P.P. Meijerink +13 more
TL;DR: Immature cluster/early T-cell precursor acute lymphoblastic leukemia patients treated on the COALL-97 protocol did not have an overall inferior outcome, and demonstrated equal sensitivity levels to most conventional therapeutic drugs compared to other pediatric T- cell acute lymphoblast leukemia patients.